I think a risk factor has to be added to NTA, it works out to be about $690m from my rough calculations, but $456m of that is "biological assets".
I havent gone through the history to see if or how much a price decline might effect that valuation, if there was long term expected price declines that couldnt be mitigated, that would reduce that $456 million.
So if there was expected price declines of say, 15% (to pick an easy number), that would reduce NTA by 10%.
Thats me trying to see possible risks though, im not suggesting it will happen, but maybe thats how the bears think about a bottom price.
Expand